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Abstract  
 
Background: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite 
measure of disease activity in axial spondyloarthritis.  
Objectives: Our aims were to investigate the most appropriate ASDAS-C-reactive protein 
(ASDAS-CRP) calculation method when the conventional CRP (cCRP) is below the limit of 
detection, to study the arithmetic influence of low CRP values obtained by high sensitivity 
CRP (hsCRP) in ASDAS-CRP results and to test agreement between different ASDAS formulae. 
Methods: Patients with axial spondyloarthritis and cCRP below the limit of detection (5mg/L, 
n=257) were selected. ASDAS-cCRP was calculated using eleven imputation strategies for the 
cCRP (range 0-5, at 0.5 intervals). ASDAS-hsCRP and ASDAS-ESR were also calculated. 
Agreement between ASDAS formulae was tested. 
Results: ASDAS-CRP calculated with the cCRP imputation values of 1.5 and 2.0mg/L and 
ASDAS-erythrocyte sedimentation rate (ESR) had better agreement with ASDAS-hsCRP than 
other imputed formulae. Disagreement was mainly in lower disease activity states 
(inactive/moderate disease activity). When the CRP value is <2mg/L, the CRP component of 
the ASDAS-CRP formula can take very low values that may result in inappropriately low 
ASDAS-CRP values. 
Conclusion: When the cCRP is below the limit of detection or when the hsCRP is <2mg/L, the 
constant value of 2mg/L should be used to calculate ASDAS-CRP. There is good agreement 
between ASDAS-hsCRP and ASDAS-ESR; however, formulae are not interchangeable. 
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 The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to 
assess disease activity in axial spondyloarthritis (SpA).[1-3] It combines five single disease 
activity variables in such a manner that it optimally conveys information, resulting in one 
single score with better truth (validity), enhanced discriminative capacity and improved 
ability to detect change as compared to separate variables.[1-5] ASDAS cut-offs have been 
developed to define disease activity states and response criteria to treatment.[2] 
ASDAS has been endorsed by the Assessment of SpondyloArthritis international 
Society (ASAS) and by the Outcome Measures in Rheumatology (OMERACT) study group and 
validated in various populations worldwide.[5-10] The ASAS membership has selected the 
ASDAS containing C-reactive protein (CRP) as the preferred version and the ASDAS 
containing erythrocyte sedimentation rate (ESR) as the alternative version.[1-3] The same 
validated cut-offs apply to both ASDAS-CRP and ASDAS-ESR.[2] 
The development and validation of the ASDAS was based on values with conventional 
CRP (cCRP). It was suggested that when the cCRP is below the limit of detection, and high 
sensitivity CRP (hsCRP) is not available, 50% of the threshold value should be used to 
calculate ASDAS-CRP.[2] However, neither this recommendation nor the effect of using 
hsCRP was data driven and requires further testing.  
The aims of this study were to investigate the best way to calculate the ASDAS when 
the cCRP is below the limit of detection, to study the arithmetic influence of low CRP values 
as obtained by hsCRP in ASDAS-CRP results and to test agreement between different ASDAS 
formulae. 
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METHODS 
 
Patients 
Baseline data from the Devenir des Spondylarthropathies Indifférenciées Récentes 
(DESIR) cohort was used. Details of the DESIR cohort have been previously described.[11] 
Briefly, DESIR is a French prospective, multicenter study of patients with early (<3 years) 
inflammatory back pain (IBP) suggestive of SpA. A total of 708 patients were included in the 
DESIR cohort at baseline. For this study, we selected all patients fulfilling the ASAS 
classification criteria for axial SpA with a cCRP value below the limit of detection and 
available hsCRP, and we have used baseline assessments only. We used the dataset locked 
on December 12th, 2011.  
 
ASDAS Calculation 
ASDAS-CRP and ASDAS-ESR were calculated based on 5 variables, one of the them 
being an acute phase reactant (either CRP or ESR) and the other four being patient-reported 
items,[1, 2] namely back pain (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] 
question 2), duration of morning stiffness (BASDAI question 6), peripheral pain/swelling 
(BASDAI question 3) and patient global assessment of disease activity. All the patient-
reported variables were captured on a 0-10 numerical rating scale. ASDAS values were also 
categorised according to previously published cut-offs for disease activity states: inactive 
disease (ASDAS<1.3), moderate (1.3≤ASDAS<2.1), high (2.1≤ASDAS≤3.5) and very high 
disease activity (ASDAS>3.5).[2]  
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The ASDAS formulae are presented below: 
a) ASDAS-CRP = 0.12*Back Pain + 0.06*Duration of Morning Stiffness + 0.11*Patient 
Global + 0.07*Peripheral Pain/Swelling + 0.58*LN(CRP (mg/L) +1) 
b) ASDAS-ESR = 0.08*Back Pain + 0.07*Duration of Morning Stiffness + 0.11*Patient 
Global + 0.09*Peripheral Pain/Swelling + 0.29*√(ESR (mm/h)) 
The limit of detection of the cCRP assay was 5 mg/L. ASDAS-cCRP was calculated 
using eleven different imputation strategies to replace the undetermined cCRP value, from 
0mg/L (ASDAS-CRP(0)) to 5mg/L (ASDAS-CRP(5)), at 0.5mg/L intervals. hsCRP was measured 
by particle-enhanced immunoturbidimetry on a Cobas Integra 800 or ModularAnalytics P800 
device (Roche Diagnostic System, Basel, Switzerland) according to the manufacturer’s 
specifications in a biological resources centre (Paris Bichat, Joëlle Benessiano).  
To gain insight into the influence of low CRP values in the total ASDAS-CRP result, we 
plotted CRP values against the CRP term (0.58*LN(CRP+1)) of the ASDAS-CRP formula and 
created a table displaying ASDAS-CRP results for different CRP values (from 0 to 5mg/L) and 
different fixed values (from 0 to 5 units) for all the other items of the ASDAS-CRP formula. 
 
Statistical analysis 
The 2-way mixed model, absolute agreement type, single measures intraclass 
correlation coefficient (ICC) was used to assess agreement between ASDAS-hsCRP and other 
ASDAS formulae (ASAS-cCRP with different imputation strategies and ASDAS-ESR). The ICC 
can have values between 0 (no agreement at all) and 1 (perfect agreement).   
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Scatter plots were created to provide an additional view of the deviation of ASDAS-
cCRP and ASDAS-ESR from ASDAS-hsCRP. Mean differences (and 95% confidence intervals) 
between ASDAS-hsCRP and others ASDAS formulae were also calculated. 
Agreement between ASDAS disease activity states was assessed using the kappa 
statistics. The kappa statistic represents the actual agreement beyond chance as a 
proportion of the potential agreement beyond chance. Since disease activity states are 
ordered categories, we used the weighted kappa. The kappa coefficient can have values 
between 0 (no agreement better than chance) and 1 (perfect agreement). 
The strenght of agreement was interpreted as follows: <0.20, poor; 0.21-0.40, fair; 
0.41-0.60, moderate; 0.61-0.80, good; 0.81-1.00, very good. SPSS v22 and MedCalc v13.1 
were used in the statistical analyses. 
 
RESULTS 
 
Patients’ characteristics 
A total of 260 patients fulfilled the inclusion criteria. Three patients had missing 
ASDAS and therefore data from 257 patients was available. Supplementary table 1 shows 
the demographic and clinical characteristics of the study population.  
 
Agreement between ASDAS formulae 
Table 1 shows the level of agreement between ASDAS formulae, both as a 
continuous and as a categorical (disease activity states) variable.  
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Quantitatively, agreement between ASDAS-hsCRP and ASDAS-cCRP with the imputed 
values of 1.0, 1.5, 2.0 and 2.5mg/L was best and very similar (ICC=0.94, 0.95, 0.94 and 0.92, 
respectively, representing very good agreement). Agreement between ASDAS-hsCRP and 
ASDAS-ESR was also very good (ICC=0.91) (table 1). 
Scatter plots (figure 1) showed that cCRP imputation values ≤1.0mg/L resulted in 
systematically lower values of ASDAS-cCRP compared to ASDAS-hsCRP while cCRP 
imputation values ≥2.5mg/L resulted in systematically higher values of ASDAS-cCRP 
compared to ASDAS-hsCRP. 
Qualitatively, agreement between ASDAS-hsCRP and ASDAS-cCRP disease activity 
states was best with the cCRP imputation values of 1.5 and 2mg/L (weighted kappa=0.75 and 
0.76, respectively, representing good agreement) (table 1). Agreement between ASDAS-
hsCRP and ASDAS-ESR disease activity states was also good (weighted kappa=0.69).  
Disease activity states according to ASDAS-CRP(1.5) and ASDAS-CRP(2) had 78.2% and 
78.1% agreement with ASDAS-hsCRP disease activity states, respectively. This percentage 
decreased to 53.3-75.6% with other imputation strategies. Disagreement was mainly in 
lower disease activity states, namely shifts between inactive disease and moderate disease 
activity (supplementary table 2). 
 
Effect of low CRP values in ASDAS-CRP results 
Supplementary figure 1 is the graphic representation of y=0.58*LN(CRP+1), the “CRP 
term” of the ASDAS-CRP formula, for CRP values between 0 and 5mg/L. The function 
approximates y=0 asymptotically. For higher values the relationship between CRP and 
0.58*LN(CRP+1) is roughly linear. However, for lower values, small differences in the CRP 
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value represent larger steps in the term 0.58*LN(CRP+1) because the steepness of the curve 
increases in this area, which may result in inappropriately low ASDAS values. This implies 
that it may be better not to allow the CRP value to be too low when calculating ASDAS-CRP. 
The decision about the optimal CRP threshold value can be done by looking at hypothetical 
case scenarios (graphically it can already be seen that this threshold should be between 1.5 
and 2.5 mg/L).  
 Table 2 is a matrix with ASDAS-CRP results for hypothetical scenarios with different 
CRP values and different fixed values for all the other four items of the ASDAS-CRP formula. 
The 1.5, 2.0 and 2.5mg/L imputation strategies perform well with very subtle differences. 
However, looking at individual cases is particularly informative; for example: 
a) if all the other variables are equal to 4, disease activity is moderate using the CRP 
constant value of 1.5 (ASDAS=2.0) but high using the CRP constant value of 2 
(ASDAS=2.1): clinically the last scenario makes more sense;  
b) if all the other variables are equal to 1.5, disease activity is moderate (ASDAS=1.3) 
using the CRP constant value of 2.5 but inactive disease (ASDAS=1.2) using the 
CRP constant value of 2: again, clinically the last scenario makes more sense.  
These two examples favour the use of the constant value of 2mg/L rather than 1.5 or 
2.5mg/L as the ideal imputation strategy for very low CRP. 
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DISCUSSION 
The availability of cCRP and hsCRP determinations in the DESIR cohort allowed us to 
perform this analysis in a large population of patients with early IBP fulfilling the ASAS 
classification criteria for axial SpA. Our study shows that when the cCRP value is below the 
limit of detection, the value of 2mg/L should be used to calculate ASDAS-CRP. Furthermore, 
when the hsCRP value is below 2mg/L, the constant value of 2mg/L should also be used to 
calculate ASDAS-CRP.  
We have shown that for very low hsCRP values small differences represent larger 
steps in the CRP term of the ASDAS formula and therefore larger steps in the total ASDAS-
CRP value. The final choice of the best imputation value was made by looking at a matrix of 
clinical scenarios (table 2) according to different imputation strategies. Differences between 
the imputation of the 1.5, 2.0 and 2.5mg/L CRP values were small, but the analysis of 
individual cases regarding the repercussion of these different imputation strategies in ASDAS 
disease activity states allowed us to conclude that the best option was not to use hsCRP 
values below 2mg/dl. 
Disagreement between ASDAS-hsCRP and other ASDAS formulae was mainly in lower 
disease activity states (inactive disease/moderate disease activity), a shift that has less 
therapeutic implications than the shift between moderate and high/very high disease 
activity. This is particularly important given recent evidence that the ASDAS cut-off for high 
disease activity (ASDAS≥2.1) is likely to be the most appropriate ASDAS cut-off to select 
patients for TNF-blocker treatment, including accumulated evidence supporting the 
replacement of the commonly used BASDAI selection cut-off of 4 units (0-10 scale) by the 
ASDAS high disease activity cut-off.[12-14] There was also a high level of agreement 
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between ASDAS-hsCRP and ASDAS-ESR. However, it is important to highlight that formulae 
are not interchangeable. 
One of the limitations of our study is the fact that this is a selected population with 
early disease. Therefore results might not be generalizable to the entire spectrum of axial 
SpA patients, in particular to patients with advanced disease/ankylosing spondylitis. 
However, the lack of generalizability is unlikely given by the fact that CRP is more frequently 
elevated in AS than in non-radiographic axial SpA, so the need to substitute cCRP values 
below the limit of detection or very low hsCRP values will occur more often in early disease 
than in late disease.[15]   
ASDAS is increasingly being used as a measure of disease activity in clinical practice, 
clinical trials and observational studies.[14] This study contributes to further standardization 
of the ASDAS and to a more homogeneous and reproducible application of this new index. 
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Table 1 Agreement between ASDAS-hsCRP and other ASDAS formulae (ASDAS-cCRP with multiple imputation 
strategies* and ASDAS-ESR) 
ASDAS formulae 
ASDAS-hsCRP 
ASDAS values ASDAS disease activity states 
ICC (95% CI) Mean difference (95% CI) Weighted kappa (95% CI) 
ASDAS-CRP(0) 0.78 (-0.06 to 0.94) -0.52 (-1.02 to -0.03) 0.51 (0.44 to 0.57) 
ASDAS-CRP(0.5) 0.89 (0.33 to 0.96) -0.29 (-0.79 to 0.21) 0.73 (0.67 to 0.79) 
ASDAS-CRP(1) 0.94 (0.89 to 0.96) -0.12 (-0.62 to 0.38) 0.73 (0.67 to 0.79) 
ASDAS-CRP(1.5) 0.95 (0.93 to 0.96) 0.01 (-0.49 to 0.51) 0.75 (0.69 to 0.81) 
ASDAS-CRP(2) 0.94 (0.90 to 0.96) 0.11 (-0.38 to 0.61) 0.76 (0.70 to 0.81) 
ASDAS-CRP(2.5) 0.92 (0.70 to 0.96) 0.20 (-0.29 to 0.70) 0.71 (0.65 to 0.77) 
ASDAS-CRP(3) 0.89 (0.37 to 0.96) 0.28 (-0.22 to 0.78) 0.66 (0.60 to 0.73) 
ASDAS-CRP(3.5) 0.86 (0.11 to 0.96) 0.35 (-0.15 to 0.85) 0.64 (0.58 to 0.70) 
ASDAS-CRP(4) 0.83 (0.00 to 0.95) 0.41 (-0.09 to 0.91) 0.61 (0.54 to 0.67) 
ASDAS-CRP(4.5) 0.81 (-0.04 to 0.94) 0.47 (-0.03 to 0.96) 0.59 (0.53 to 0.65) 
ASDAS-CRP(5) 0.78 (-0.06 to 0.94) 0.52 (0.02 to 1.01) 0.50 (0.44 to 0.57) 
ASDAS-ESR 0.91 (0.85 to 0.94) 0.13 (-0.52 to 0.79) 0.69 (0.63 to 0.76) 
*ASDAS-CRP(0) to ASDAS-CRP(5) represents the ASDAS-CRP results with eleven imputation strategies for the conventional CRP, 
from 0 to 5mg/L, at 0.5mg/L intervals. ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; CI, confidence 
interval; ESR, erythrocyte sedimentation rate; ICC, intraclass correlation coefficient; hs, high sensitivity. The total number of 
patients is 257, except for the ASDAS-ESR analysis where the total number of patients is 246. 
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 Table 2 ASDAS-CRP results for different CRP values (from 0 to 5mg/L, at 0.5mg intervals) and different fixed values (from 0 to 5 units, at 0.5 units intervals) for all the other four 
items in the ASDAS-CRP formula 
CRP (mg/L) 
ASDAS-CRP 
All other 
variables=0 
All other 
variables=1 
All other 
variables=1.5 
All other 
variables=2 
All other 
variables=2.5 
All other 
variables=3 
All other 
variables=3.5 
All other 
variables=4 
All other 
variables=4.5 
All other 
variables=5 
0 0.0 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.6 1.8 
0.5 0.2 0.6 0.8 1.0 1.1 1.3 1.5 1.7 1.9 2.0 
1 0.4 0.8 0.9 1.1 1.3 1.5 1.7 1.8 2.0 2.2 
1.5 0.5 0.9 1.1 1.3 1.4 1.6 1.8 2.0 2.2 2.3 
2 0.6 1.0 1.2 1.4 1.5 1.7 1.9 2.1 2.3 2.4 
2.5 0.7 1.1 1.3 1.4 1.6 1.8 2.0 2.2 2.3 2.5 
3 0.8 1.2 1.3 1.5 1.7 1.9 2.1 2.2 2.4 2.6 
3.5 0.9 1.2 1.4 1.6 1.8 2.0 2.1 2.3 2.5 2.7 
4 0.9 1.3 1.5 1.7 1.8 2.0 2.2 2.4 2.6 2.7 
4.5 1.0 1.3 1.5 1.7 1.9 2.1 2.2 2.4 2.6 2.8 
5 1.0 1.4 1.6 1.8 1.9 2.1 2.3 2.5 2.7 2.8 
ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein. All values are rounded to one decimal place. Light grey, inactive disease; grey, moderate disease 
activity; dark grey, high disease activity. 
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 Figure 1 ASDAS-hsCRP plotted against other ASDAS formulae (ASDAS-cCRP with different 
imputation strategies and ASDAS-ESR). The diagonal line indicates exact agreement between the 
ASDAS formulae; total n=257, except for the ASDAS-ESR scatter plot where n=246. 
 
 
Supplementary figure 1 Graphic displaying the results of the CRP component of the ASDAS-CRP 
formula (0.58*LN(CRP+1)) according to the CRP value, from 0 to 5mg/L, at 0.1 mg/L intervals. 
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